Cargando…

RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes

Standard radiation therapy (RT) does not reliably provide locoregional control for women with multinode-positive breast cancer and triple-negative breast cancer (TNBC). We hypothesized that CDK4/6 inhibition (CDK4/6i) would increase the radiosensitivity not only of estrogen receptor–positive (ER(+))...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pesch, Andrea M., Hirsh, Nicole H., Michmerhuizen, Anna R., Jungles, Kassidy M., Wilder-Romans, Kari, Chandler, Benjamin C., Liu, Meilan, Lerner, Lynn M., Nino, Charles A., Ward, Connor, Cobain, Erin F., Lawrence, Theodore S., Pierce, Lori J., Rae, James M., Speers, Corey W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855810/ https://www.ncbi.nlm.nih.gov/pubmed/34932500 http://dx.doi.org/10.1172/jci.insight.154402

Ejemplares similares

Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression
por: Pesch, Andrea M., et al.
Publicado: (2022)

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models
por: Michmerhuizen, Anna R., et al.
Publicado: (2022)

Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models
por: Michmerhuizen, Anna R., et al.
Publicado: (2022)

Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer
por: Michmerhuizen, Anna R., et al.
Publicado: (2022)

Development and Validation of a Novel Platform-Independent Metastasis Signature in Human Breast Cancer
por: Zhao, Shuang G., et al.
Publicado: (2015)

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)

ARe we there yet? Understanding androgen receptor signaling in breast cancer
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

A novel role for TTK in homologous recombination: implications for breast cancer radiosensitivity
por: Chandler, Benjamin C., et al.
Publicado: (2020)

Degrading AR-Dependent Cancers: Expanding the Role of PROTACs
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Speers, Corey, et al.
Publicado: (2017)

Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment
por: Speers, Corey, et al.
Publicado: (2017)

Cdk6: At the interface of Rb and p53
por: Nebenfuehr, Sofie, et al.
Publicado: (2018)

Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
por: Hagen, Katie R, et al.
Publicado: (2013)

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
por: Kregel, Steven, et al.
Publicado: (2020)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

Complete Genome Sequences of T4-Like Bacteriophages RB3, RB5, RB6, RB7, RB9, RB10, RB27, RB33, RB55, RB59, and RB68
por: Yaung, Stephanie J., et al.
Publicado: (2015)

CDK4, pRB and E2F1: connected to insulin
por: Fajas, Lluis, et al.
Publicado: (2010)

Regulation of Rb family proteins by Cdk6/Ccnd1 in growth plates
por: Komori, Toshihisa
Publicado: (2013)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
por: Kim, Sungsoo, et al.
Publicado: (2022)

The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression
por: Niknafs, Yashar S., et al.
Publicado: (2016)

High-content CRISPR screening in tumor immunology
por: Holcomb, Erin A., et al.
Publicado: (2022)

SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
por: Meng, Fengxi, et al.
Publicado: (2016)

Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells
por: Li, Songyu, et al.
Publicado: (2020)

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
por: Maelandsmo, G. M., et al.
Publicado: (1996)

To Rb or not to Rb
por: Wells, William A.
Publicado: (2002)

p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells
por: Brugarolas, James, et al.
Publicado: (1998)

The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma
por: Tsuda, H, et al.
Publicado: (2000)

Functional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast Cancer Cells
por: Varma, Hemant, et al.
Publicado: (2007)

Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB.
por: Schade, Amy E., et al.
Publicado: (2019)

Sertad1 Induces Neurological Injury after Ischemic Stroke via the CDK4/p-Rb Pathway
por: Li, Jianxiong, et al.
Publicado: (2022)

The Regulatory Role of miR-107–Cdk6-Rb Pathway in Airway Smooth Muscle Cells in Asthma
por: Xiong, Yi, et al.
Publicado: (2023)

Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner
por: Kim, Su-Jung, et al.
Publicado: (2023)

The beta-decay of $^{95}$Rb and $^{97}$Rb
por: Kratz, K L, et al.
Publicado: (1983)

CDK-inhibitor independent cell cycle progression in an experimental haematopoietic stem cell leukaemia despite unaltered Rb-phosphorylation
por: Huss, R, et al.
Publicado: (1999)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Vijayaraghavan, Smruthi, et al.
Publicado: (2017)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

RB depletion is required for the continuous growth of tumors initiated by loss of RB
por: Doan, Alex, et al.
Publicado: (2021)

Cdk5-mediated inhibition of APC/C-Cdh1 switches on the cyclin D1-Cdk4-pRb pathway causing aberrant S-phase entry of postmitotic neurons
por: Veas-Pérez de Tudela, Miguel, et al.
Publicado: (2015)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uent8jknqkclq59rqfop2be9f5